A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus (T2DM)

In brief

To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK and PD of multiple doses of KHK.

Key facts

Study ID
NCT05761301
Run by
Alnylam Pharmaceuticals
People needed
49
Starts
2023-03-10
Expected to finish
2025-04-03
Last updated by the study team
2025-05-07

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.